Sanofi isn’t saying how much it is paying for the OTC rights to Tamiflu in the US ... as Tamiflu continues to decline, with the older brand reduced to just $179m in the first quarter of this ...
"Nexium is one of the most recognised and respected products in its class with tremendous brand ... Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback